Hetero-stereocomplex formation of stereoblock copolymer of substituted and non-substituted poly(lactide)s

The crystallization behavior of the stereoblock copolymer of substituted and non-substituted poly(lactide)s, i.e., poly(d-2-hydroxybutyrate) and poly(l-lactide) chains having the opposite configurations [P(D-2HB)-b-PLLA] and the reference block copolymer of poly(d-2-hydroxybutyrate) and poly(d-lactide) chains with the identical configurations [P(D-2HB)-b-PDLA] was investigated. At the crystallizable temperature range of 60-160 °C, the crystallized P(D-2HB)-b-PLLA contained solely the hetero-stereocomplex crystallites as a crystalline species, without formation of poly(d-2-hydroxybutyrate) or poly(l-lactide) homo-crystallites, in contrast with their polymer blends. On the other hand, at the crystallizable temperature range of 60-140 °C, the crystallized P(D-2HB)-b-PDLA had only PDLA homo-crystallites as crystalline species, reflecting no co-crystallites formation between poly(d-2-hydroxybutyrate) and poly(d-lactide) chains having the same configurations. The equilibrium melting temperature of hetero-stereocomplex crystallites in P(D-2HB)-b-PLLA was 189.0 °C, which was higher than 171.3 °C of PDLA homo-crystallites in P(D-2HB)-b-PDLA. Although the final crystallinity of P(D-2HB)-b-PLLA was higher than those of P(D-2HB)-b-PDLA, the spherulite growth rate of P(D-2HB)-b-PLLA was lower.The regime analysis indicated unusual nucleation mechanism of P(D-2HB)-b-PLLA.     

Effects of supercritical carbon dioxide treatment on the morphology of poly(l‐lactide)

Synthetic l ‐lactide random copolymers can be employed as controlled release materials when prepared using supercritical carbon dioxide (scCO₂), since they are biodegradable via hydrolysis. To determine the effects of thermal properties on polymer performance following scCO₂ processing, three types of poly(l ‐lactide) having different properties were assessed. The T_m of one poly(l ‐lactide) sample (H‐100) was found to be approximately 170 °C over the processing pressure range from 8 to 18 MPa, while a second sample (H‐440) also showed a constant value of approximately 152 °C. In contrast, the poly(l ‐lactide) REVODE exhibited a T_m of 146 °C prior to processing but a higher value of 147 °C following treatment at 8 MPa. Unlike the H‐100 and H‐440, the T_m value of the REVODE tended to decrease with increasing pressure. The T_g values increased greatly under mild conditions of 8 MPa pressure and a temperature of 40 °C. In particular, the T_g values for the H‐440 and REVODE increased by 4 °C and 5 °C, respectively. All T_g values were lowest at 12 MPa and increased with increasing processing pressure, although the effect of processing temperature was minimal. The Χ_{c DSC} of the H‐100 was 18% initially but increased to 20% upon scCO₂ processing at 40 °C and 14 MPa, and showed further increases at higher processing temperatures. Although the relationship between processing temperature and Χ_{c DSC} values for the H‐440 showed the same trend as observed with the H‐100, a different trend was seen for the REVODE. The Χ_{c XRD} values obtained from the XRD analyses differed from the values generated by DSC analysis, and showed a maximum degree of crystallinity following processing at 80 °C both with and without scCO₂ treatment. ATR FT‐IR analyses identified peaks due to semicrystalline regions in poly(l ‐lactide) samples treated with scCO₂, even when applying low temperatures. © 2016 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2016 , 133, 44006.     

Impact of Oncogenic Targets by Tumor-Suppressive miR-139-5p and miR-139-3p Regulation in Head and Neck Squamous Cell Carcinoma

We newly generated an RNA-sequencing-based microRNA (miRNA) expression signature of head and neck squamous cell carcinoma (HNSCC). Analysis of the signature revealed that both strands of some miRNAs, including miR-139-5p (the guide strand) and miR-139-3p (the passenger strand) of miR-139, were downregulated in HNSCC tissues. Analysis of The Cancer Genome Atlas confirmed the low expression levels of miR-139 in HNSCC. Ectopic expression of these miRNAs attenuated the characteristics of cancer cell aggressiveness (e.g., cell proliferation, migration, and invasion). Our in silico analyses revealed a total of 28 putative targets regulated by pre-miR-139 (miR-139-5p and miR-139-3p) in HNSCC cells. Of these, the GNA12 (guanine nucleotide-binding protein subunit alpha-12) and OLR1 (oxidized low-density lipoprotein receptor 1) expression levels were identified as independent factors that predicted patient survival according to multivariate Cox regression analyses (p = 0.0018 and p = 0.0104, respectively). Direct regulation of GNA12 and OLR1 by miR-139-3p in HNSCC cells was confirmed through luciferase reporter assays. Moreover, overexpression of GNA12 and OLR1 was detected in clinical specimens of HNSCC through immunostaining. The involvement of miR-139-3p (the passenger strand) in the oncogenesis of HNSCC is a new concept in cancer biology. Our miRNA-based strategy will increase knowledge on the molecular pathogenesis of HNSCC.     

Pulverization mechanism of hydrogen storage alloys on microscale packing structure

In-situ and transient visualizations of the packing structure of a hydrogen storage alloy bed are carried out using an X-ray computed tomography (CT) system. The packing structure is clearly observed on the microscale using the CT system. When the alloy bed is subjected to hydrogen absorption–desorption cycles, the pulverization progresses from the lower to the upper regions of the bed. After several hydrogen absorption–desorption cycles, the packing structure in the lower region of the bed changes and the microstructural void decreases slightly. Based on these results, we propose a pulverization mechanism of the packed bed in which the friction between particles affects the pulverization process.     

Beta-1,3 Oligoglucans Specifically Bind to Immune Receptor CD28 and May Enhance T Cell Activation

Beta glucans are known to have immunomodulatory effects that mediated by a variety of mechanisms. In this article, we describe experiments and simulations suggesting that beta-1,3 glucans may promote activation of T cells by a previously unknown mechanism. First, we find that treatment of a T lymphoblast cell line with beta-1,3 oligoglucan significantly increases mRNA levels of T cell activation-associated cytokines, especially in the presence of the agonistic anti-CD3 antibody. This immunostimulatory activity was observed in the absence of dectin-1, a known receptor for beta-1,3 glucans. To clarify the molecular mechanism underlying this activity, we performed a series of molecular dynamics simulations and free-energy calculations to explore the interaction of beta-1,3 oligoglucans with potential immune receptors. While the simulations reveal little association between beta-1,3 oligoglucan and the immune receptor CD3, we find that beta-1,3 oligoglucans bind to CD28 near the region identified as the binding site for its natural ligands CD80 and CD86. Using a rigorous absolute binding free-energy technique, we calculate a dissociation constant in the low millimolar range for binding of 8-mer beta-1,3 oligoglucan to this site on CD28. The simulations show this binding to be specific, as no such association is computed for alpha-1,4 oligoglucan. This study suggests that beta-1,3 glucans bind to CD28 and may stimulate T cell activation collaboratively with T cell receptor activation, thereby stimulating immune function.     

Gamma delta TCR-bearing intraepithelial lymphocytes regulate class II major histocompatibility complex molecule expression on the mouse small intestinal epithelium

OBJECTIVE: To examine the hypothesis that addition of therapeutic plasma exchange (TPEX) to an immunosuppressive drug regimen increases that regimen's efficacy to halt the progression of chronic progressive multiple sclerosis (CPMS). METHODS: The literature was searched for prospective controlled clinical trials evaluating the efficacy of TPEX in CPMS. Six studies were eligible for meta-analysis. Their results were combined, using Cochran's and Peto's methods. Three outcome measures were studied: 1) the change in Kurtzke's disability status scale (DSS) scores, 2) the relative odds of neurologic decline by 1 or more DSS grades, and 3) the relative odds of neurologic improvement by 1 or more DSS grades, in the treatment versus the comparison group of patients. Reported results of neurologic evaluations at 6, 12, 24, and 36 months of follow-up were analyzed separately. RESULTS: TPEX significantly (P < .05) reduced the proportion of patients who experienced neurologic decline (by 1 or more DSS grades) at 12 months of follow-up (relative odds of decline = 0.441, 95% confidence interval = 0.210-0.929). CONCLUSIONS: There is a need for further clinical research into the possibility of a beneficial effect of TPEX in patients with CPMS likely to experience neurologic decline over the ensuring 12 months. Targeting treatment to a particular subgroup of CPMS patients may be necessary for TPEX to prove effective.     

Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas

In the treatment of adenocarcinoma of the pancreas, surgical resection is the only curative strategy. However, the long-term survival rate after pancreatectomy remains poor, and most patients died of loco-regional and/or hepatic recurrence. Thus, we should perform effective adjuvant therapies in combination with surgery, in order to completely prevent these two types of cancer relapse. The present article is designed to introduce the recent reports on the adjuvant chemo-and/or radio-therapies for this cancer. As for loco-regional control, extended pancreatectomy plus chemoradiation seems to be most promising, and preoperative chemoradiation will be more popular in the near future. In order to decrease hepatic metastasis, our "2-channel chemotherapy", a continuous infusion of 5-FU via both hepatic artery and portal vein, is very promising. If postoperative survival is improved by combining these two types of regional therapy, the role of pancreatectomy will be enlarged and more widely understood in the near future.     

Biosynthesis and characterization of novel polyhydroxyalkanoate copolymers consisting of 3-hydroxy-2-methylbutyrate and 3-hydroxyhexanoate

In this study, in order to explore the possibility of biosynthesizing a novel polyhydroxyalkanoate (PHA), copolymerization of 3-hydroxy-2-methylbutyrate (3H2MB) as the α-position methylated monomer and 3-hydroxyhexanoate (3HHx) as the medium-chain-length monomer was performed to obtain P(3H2MB-co-3HHx). The β-oxidation-deficient Escherichia coli LSBJ, harboring the PHA biosynthetic operon from Aeromonas caviae and the propionyl-CoA transferase gene (pct) from Megasphaera elsdenii, was cultured with feeding tiglic and hexanoic acids as the precursors for 3H2MB and 3HHx, respectively. It was observed that pct expression was highly effective to enhance the incorporation of 3H2MB into PHA. The biosynthesized PHA was composed of 3H2MB and 3HHx units only, and the 3H2MB fraction varied in the range of 36–60 mol% depending on the culture conditions. These PHAs exhibited glass transition temperatures between ?11 to ?17 °C; moreover, no melting peak was observed during analysis using differential scanning calorimetry. This study demonstrated the biosynthesis of a hitherto unreported PHA by engineering metabolic pathway in E. coli.